Case Study
Building an AI-Driven Imaging Platform for a Global Biotech Leader
Production-ready AI imaging pipeline. Deployed in under 10 weeks.
What needed to change
As imaging data volumes and clinical complexity increased globally, the organization faced mounting challenges across data management, regulatory compliance, and operational efficiency. Disconnected systems and manual workflows slowed access to critical insights and limited the pace of innovation across clinical trials, R&D, and commercialization efforts.
Fragmented Imaging Data: Clinical and imaging data scattered across regions and systems with no unified access layer, creating blind spots across therapeutic areas.
Regulatory Scrutiny: Increasing FDA compliance requirements for data validation, auditability, and governance that existing workflows could not meet.
Slow Time to Insight: Manual validation and review processes delaying access to critical imaging results by up to four weeks.
R&D Velocity Constraints: Operational bottlenecks limiting the pace of clinical trials, R&D cycles, and commercialization timelines.
Rising Costs and Compliance Risk: Elevated operational costs, missed revenue opportunities, and growing legal exposure from non-compliance.
What we built
NextPhase.ai designed and implemented a global, AI-driven imaging platform aligned with the organization's existing technology ecosystem and regulatory requirements, deployed production-ready in under 10 weeks across oncology, neurology, and ophthalmology therapeutic areas.
Global Imaging Platform: Unified imaging data across regions and systems into a single governed, scalable environment with full lineage and audit capability.
Dynamic AI Algorithms: Specialized models supporting oncology, neurology, and ophthalmology, including a tumor detection algorithm recognized and published by the American Society of Hematology.
Built-In FDA Compliance: Data validation and governance workflows designed to meet FDA standards from day one, not retrofitted after deployment.
Integrated Analytics: Advanced imaging analytics enabling faster, more informed decision-making across clinical and R&D teams globally.
What it delivered
The modernized imaging platform delivered measurable improvements across clinical operations, regulatory confidence, and R&D velocity. Full production deployment completed in under 10 weeks.
4 Weeks to 1 Day: Validated imaging data now accessible in one day instead of four weeks, enabling faster clinical decisions.
40% Validation Efficiency Gain: FDA-related data validation accelerated by 40%, directly speeding clinical and R&D timelines.
Deployed in Under 10 Weeks: Full production deployment including AI models, governance workflows, and system integrations.
Regulatory Confidence: Strengthened FDA compliance posture, significantly reducing non-compliance risk and audit exposure.
Published Research Impact: Tumor detection algorithm recognized and published by the American Society of Hematology.
Got a use case stuck in planning, pilot, or proof-of-concept?
Book a 30-minute working session. We will scope your use case, surface the real blockers, and tell you straight what a production path looks like.